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Abstract
Background: Variance in microarray studies has been widely discussed as a critical topic on the identification of
differentially expressed genes; however, few studies have addressed the influence of estimating variance.
Methodology/Principal Findings: To break intra- and inter-individual variance in clinical studies down to three levels–
technical, anatomic, and individual–we designed experiments and algorithms to investigate three forms of variances. As a
case study, a group of ‘‘inter-individual variable genes’’ were identified to exemplify the influence of underestimated
variance on the statistical and biological aspects in identification of differentially expressed genes. Our results showed that
inadequate estimation of variance inevitably led to the inclusion of non-statistically significant genes into those listed as
significant, thereby interfering with the correct prediction of biological functions. Applying a higher cutoff value of fold
changes in the selection of significant genes reduces/eliminates the effects of underestimated variance.
Conclusions/Significance: Our data demonstrated that correct variance evaluation is critical in selecting significant genes. If
the degree of variance is underestimated, ‘‘noisy’’ genes are falsely identified as differentially expressed genes. These genes
are the noise associated with biological interpretation, reducing the biological significance of the gene set. Our results also
indicate that applying a higher number of fold change as the selection criteria reduces/eliminates the differences between
distinct estimations of variance.
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Introduction
Over the last decade, microarray studies have had a profound
impact on transcriptomic research. One particularly important
clinical application of microarray technology is the identification
of differentially expressed genes, which may serve as biomarkers
for the diagnosis and prognostic prediction of tumors or other
complex diseases [1–3]. Despite many successful results, some
studies have revealed that gene lists derived from similar studies
are highly inconsistent [4–6]. Numerous investigations have been
conducted to evaluate the influence of multiple factors, such as
batch effects [7], dye effects [8], different platforms [9–13], various
experiment designs [14–16], and statistical approaches [17,18],
regarding microarray results. However, few studies have explored
the influence of different sources of variation on the identification
of differentially expressed genes from microarray analysis.
Researchers have identified two major sources of variance in
microarray studies: technical variance and biological variance
[19]. All forms of variations influenced by experimental artifacts,
such as the quality of RNA, batch effects, and experimental
parameters, belong to technical variance. A well-conceived
experimental design and execution as well as rigorous statistical
analysis can reduce the effects of technical variation. Studies have
demonstrated that loop designs are more efficient than reference
designs in two color microarrays [14,20], and many statistical
methods can be used to increase the robustness of microarray data
analysis [21,22]. Several studies have concluded that the
reproducibility of microarrays could be improved using standard-
ized protocols and carefully designed and controlled experiments
[12,13,23].
Biological variance is attributed to specimens, rather than
procedures, and can be traced to several sources. Anatomic
variance is caused by the heterogeneous distribution of cell types
within a tissue specimen collected from a single individual [24].
Individual variance is a result of various genotypes and physio-
logical states. For variation in genotypes, copy number variations
(CNVs) [25,26] and allele variations [27,28] have been shown to
influence gene expression levels. Physiological status such as
environment factors, disease state, and other variables influence
gene expression. Many researchers have reported biological
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[33], and other tissues [34–37]. In addition, variations in gene
expression have been identified among individuals as well as
populations [38–40] and species [19,40,41]. However, the effects
of applying different levels of variances have not been well
addressed.
In this study, we used the normal human placenta as a model to
evaluate technical, anatomic, and individual variance. Each of
these types of variation should be considered in clinical studies.
The ‘‘inter-individual variable gene’’ was used as an example to
evaluate the influence of estimating variance on microarray results.
We profiled three levels of variance in human clinical studies and
addressed the importance of estimating variance on the statistical
and biological aspect for microarray studies. Our data demon-
strated that correct variance evaluation is critical in selecting
significant genes.
Materials and Methods
Specimen Collection and Processing
Eleven normal placental tissues were obtained from 9 healthy
individuals who underwent cesarean section without labor pain
[42]. This study was approved by the Institutional Review Board
of Chang Gung Memorial Hospital (IRB#96-0630B). Inclusion
criteria were healthy normotensive term pregnancies with
appropriate-for-gestational-age fetuses, who displayed no abnor-
mality on routine ultrasound scans. Exclusion criteria for this study
were fetal chromosomal abnormalities, pre- and postnatal
malformations or phenotypic anomalies, maternal smoking,
maternal obesity, and maternal diseases, such as autoimmune
diseases, thrombophilic conditions, and diabetes [43]. The clinical
information is summarized in Table 1. Placental specimens were
obtained from the same region of the placenta (5 cm away from
the site of cord insertion) immediately after delivery. The
approximate 2.5-cm thickness of the placental cross section was
divided into three equal parts: maternal (includes thin basal plate),
middle, and fetal (includes the chorionic plate) [32]. We analyzed
the middle part of the placental tissues in all of our placental
studies [42,44]. The tissues were snap frozen in liquid nitrogen and
stored at 280uC. The first sample group (G1) comprised samples 1
to 9 of 9 individuals. The second sample group (G2) contained 8–
1, 8–2, and 8–3, which were 3 different placental tissues taken
from the same individual. The third sample group (G3) consisted
of 2 technical replicates, 8–3_1 and 8–3_2, using the identical
RNA pool (Figure 1).
RNA Extraction and Microarray Hybridization
Total RNA was isolated as previously reported [45]. Because
the purpose of this study was to analyze variance of gene
expression that may be commonly encountered at the tissue level,
we did not isolate individual cell types from whole tissues. During
RNA extraction, 1 ml of Trizol reagent (Life Technologies,
Rockville, MD) was added to every 50–100 mg of pulverized
frozen placental tissue. Total RNA was isolated using the Trizol
reagent (Life Technologies, Rockville, MD). Total RNA was
quantified by UV absorption at 260 nm, and RNA quality was
examined using the Agilent 2100 bioanalyzer (Agilent technolo-
gies, USA). cDNA labeling was conducted using a 3 DNA Array
50
TM kit (Genisphere, Hatfield, PA), according to the manufac-
turer’s protocols. In brief, 20-mg total RNA was used to perform
reverse transcription reaction with SuperScript II RNase H-
reverse transcriptase and specific primers (Invitrogen life technol-
ogies, USA). All synthesized tagged cDNA targets were then
purified using the Microcon YM-30 column (Millipore, USA). The
purified targets and fluorescent 3 DNA reagents were hybridized
to the arrays in succession. Arrays were sealed in a homemade
hybridization chamber that adapted the design provided in M-
Guide (Patrick O. Brown laboratory, Stanford University, USA).
Hybridization was performed at 65uC in a water bath for 16 h,
and arrays were washed according to the manufacturer’s protocol
(http://www.genisphere.com/pdf/array50v2_10_19_04.pdf).
Subsequently, arrays were scanned with GenePix 4100A (Axon
Instruments, USA) and images were acquired using GenePix Pro
5.0 software (Axon Instruments, USA).
Production of Microarrays
We originally ordered 9600 human cDNA clones of the
IMAGE library from Incyte Genomics (Palo Alto, Calif, USA)
and allowed sequencing at that location. Only 7334 clones passed
sequence verification by Incyte Genomics and were shipped to us.
Therefore, every clone of this 7334-clone cDNA library had an
IMAGE ID, DNA sequences, vector names, and information for
PCR primers [45]. All clones were further amplified by PCR and
purified by isopropanol precipitation in 96-well plates. The
purified DNAs were resuspended in 36SSC for spotting. A single
microarray slide (CMT-GAPsII, Corning Inc., USA) contains
7334 human cDNA probes in quadruplicate, 10 spike-in genes
(SpotReportTM-10 Array Validation System, Stratagene, USA),
and one housekeeping gene, b-actin, in 96 replicates. Each array
had 32,448 spots. The arrays were post-processed as recom-
mended in the Corning UltraGAPS Coated Slides Instruction
Manual. Microarray slides were produced in a well-controlled
Figure 1. Microarray experimental design. Three kinds of samples
were employed in this study. Individual variance was evaluated using
the first sample group (G1), comprising Samples 1 to 9 of nine
individuals. The second sample group (G2) was used to evaluate
anatomic variance. It contained Samples 8–1, 8–2, and 8–3, taken from
three different sections of placenta from the same individual. The third
sample group (G3) consists of two technical replicates, Samples 8–3_1
and 8–3_2, using an identical RNA pool for microarray hybridization to
evaluate technical variance. The expression of Sample 8–3 could be
estimated by the mean expression of Samples 8–3_1 and 8–3_2. The
mean expression of Samples 8–1, 8–2, and 8–3 represented the
expression of Sample 8.
doi:10.1371/journal.pone.0038650.g001
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desiccation until use. The array system was assembled according
to M-Guide (Patrick O. Brown laboratory, Stanford University,
USA) and controlled using ArrayMaker, version 2.5.1 (Joseph
DeRisi laboratory, UCSA, USA) [46]. A rigorous system
commissioning was performed to guarantee the quality of the
printed arrays. Before hybridization, the slides were preprocessed
according to the instruction manual for the Corning UltraGAPS
Coated Slides, including rehydration, snap-dry, UV-crosslinking,
baking, and surface blocking. DNAs were UV-crosslinked with
300 mJ/cm2 using the Stratalinker 2400 UV Crosslinker (Strata-
gene, USA).
Microarray Data Analysis
The logarithm of the ratios for all valid spots on each array was
normalized by locally weighted linear regression (LOWESS).
Descriptions of Microarray Data Preprocessing can be found in
our previous studies [47]. The normalized log ratios were then
processed gene-by-gene using a log linear model [47,48]. This
model describes the normalized log ratio as follows:
log2(R=G)~czli{ljze
where c represents the relative labeling efficiency between dyes, li
is log2 (expression of sample i/mean expression of all samples) for
one specific cDNA clone, with
P 9
i~1
li~0, and e is the random error
with mean 0 and variance s
2. s represents the estimated variance
for one specific cDNA clone. For each clone, li and s are
estimated from the observed data by using the least squares
method as ^ l l and ^ s s. When the data had been processed using the
log linear model, 5501 genes could be calculated in the model
without singularity. l8{3 is estimated by
^ l l8{3~ ^ l l8{3 1z^ l l8{3 2
hi .
2. l8 is estimated by
^ l l8~ ^ l l8{1z^ l l8{2z^ l l8{3
hi .
3. A further description of the statis-
tical model can be found in Methods S1. We had developed a
Web tool for loop-design microarray data analysis [49]. All of the
front-end analyses of our microarray data were conducted using
this public available Web tool. The microarray data of this work
are MIAME compliant and have been deposited in the GEO of
NCBI (accession number: GSE27646).
Differential Expression and Averaged Fold Change
Differential expression is log2 (fold change of 2 samples) for one
specific cDNA clone and is denoted as d(i,j,x)~l
^
i(x){l
^
j(x),
where x is the index denoting clones and i,j denoting samples.
Differential expression profiles in Figure 2a are the histograms of
data set S1:li
^
(x){lj
^
(x), S2:l8{i
^
(x){l8{j
^
(x), and
S3:l8{3{1
^
(x){l8{3{2
^
(x), which are the set of all d(i,j,x) when
x runs over all clones and (i,j) runs over all possible pairs in G1, G2,
and G3, respectively. For S1, i and j range from 1 to 9. For S2, i
and j range from 8–1 to 8–3. For S3, i and j are 8–3_1 and 8–3_2,
respectively. Moreover, averaged fold change is estimated by.
2
mean
i,j
(Dd(i,j,x)D)
;
where mean
i,j
() denotes the mean over absolute expression
differences of all possible sample pairs (i,j) for clone x. It is the
indicator of fold change for individual variance.
Statistical Test
We designed a test statistic,
D(x)~
X n
i,j
di ,j,x ðÞ
^ s s
   2
;
to describe the variation of gene expression between samples. The
summation runs on every dual-color microarray experiment
(represented by an arrow in Figure 1), where x is the xth clone, i
is for the sample represented by the tail of the arrow, j is for the
Table 1. Clinical information of pregnancy outcomes (n=9).
Clinical parameter Mean ± SD* Range of this group Reference range
Maternal age (y) 32.663.7 25 , 36 NA
Gravida
# 2.661.1 1 , 4N A
Para
& 1.260.8 0 , 2N A
Maternal Hemoglobin (g/dL) 10.861.8 8.6 , 13.5 12 , 16
Mean cell volume of RBC (fL) 8367.6 72 , 92 80 , 100
Systolic blood pressure (mmHg) 117.1611.4 102 , 136 90 , 140
Diastolic blood pressure (mmHg) 62.4610.3 50 , 78 50 , 90
Gestational age (week) 38.360.9 37 , 39 38 , 40
Neonate body weight (g) 31336345 2520 , 3580 2430 , 3900
Apgar score
% (1 min) 9.060.5 8 , 10 .7
Apgar score
% (5 min) 9.960.3 9 , 10 .7
#indicates the number of times the mother has been pregnant, regardless of whether these pregnancies were carried to term. A current pregnancy, if any, is included in
this count.
&indicates the number of viable (.20 wks) births. Pregnancies consisting of multiples, such as twins or triplets, count as ONE birth for the purpose of this notation.
%is a simple and repeatable method to quickly and summarily assess the health of newborn children immediately after birth.
*is standard variation.
doi:10.1371/journal.pone.0038650.t001
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of sample pair i,j. We used the sampling permutation method to
describe the D quantity when considering three levels of variance
(Methods S1). D1, D2, and D3 are the results of 10 million times
the sampling permutation of
X n
i,j
S1
^ s s
   2
,
X n
i,j
S2
^ s s
   2
,
and
X n
i,j
S3
^ s s
   2
, for taking n data from S1, S2, and S3 at one
time. The corresponding p values of the D quantity are determined
using the smoothed curve of the probability density in Figure 2b.
The criterion of the p value for the statistical test in this study is a
false discovery rate (FDR) of 5%.
Functional Enrichment Analysis
Gene Ontology (GO)-based functional enrichment analysis is
used to measure gene enrichment in annotation terms for the
inter-individual variable genes. The significance score in Table 1
is –log (EASE Score), where the EASE Score is a modified
Fisher exact p value [50] obtained by DAVID. The GO terms
passed the criteria, EASE Score ,0.1, and at least 2 genes in
each GO term are considered for further comparison. Only 11
mutual GO terms exist for all selection criteria, and these are
shown in Table 2.
Results
Demographics of Studied Subjects
Analyzed placental tissues were collected from 9 healthy
pregnant women, whose clinical information is listed in Table 1.
All the pregnant women were free of hypertension, diabetes
mellitus, preterm labor, and other medical diseases. All neonates
were born at term and with normal body weight and healthy vital
Figure 2. Profiles of the three kinds of variance. (a) The distribution of the differential expression for the three forms of variance. The
differential expression for the three forms of variance was estimated by S1:li
^
(x){lj
^
(x), S2:l8{i
^
(x){l8{j
^
(x), and S3: l8{3{1
^
(x){l8{3{2
^
(x) for
any possible pair of i and j, respectively. (b) D1, D2, and D3 are the probability density distributions of D quantity using permutation method using
the data series S1, S2, and S3 when considering individual, anatomic, and technical variance respectively.
doi:10.1371/journal.pone.0038650.g002
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after delivery, as used previously [42–44].
The Profiles of 3 Levels of Variance
We used a loop design in a microarray analysis of normal
placental tissues to investigate technical, anatomic, and individual
variance in microarray data. Figure 1 is a schematic representation
of the interwoven loop hybridization design performed in this
study. We selected 11 normal placental tissues from 9 women with
term pregnancies, who underwent Cesarean section prior to the
onset of labor, to avoid variations caused by labor pain.
Microarray data were obtained from 3 sample groups to estimate
individual, anatomic, and technical variance. The first sample
group (G1) comprised Samples 1 to 9, samples of 9 individuals.
The second sample group (G2) contained Sample 8–1, 8–2, and 8–
3, which were 3 different placental regions taken from the same
individual. The third sample group (G3) consisted of 2 technical
replicates, Sample 8–3_1 and 8–3_2, obtained from the same
RNA pool. Differential expression profiles in Figure 2a are log
(fold change) between samples in 3 sample groups (G1, G2, and
G3) and it is the histogram of data series S1, S2, and S3,
respectively. These results were presented as distributions of the
fold changes of G1, G2, and G3. The results indicate a progressive
narrowing of distribution curves from S1 to S3, revealing that
individual difference produced a greater degree of relative
variability in gene expression than that of the anatomic or
technical difference.
A test statistic, D quantity, was designed to measure the
variation in gene expression between samples. Figure 2b shows the
probability density profiles of the D quantity, D1, D2, and D3,
representing 3 levels of variability. These profiles were generated
by applying permutation methods using the data series S1, S2, and
S3, indicating extreme differences in the 3 levels of variance.
Case Study: Inter-individual Variable Gene
In this study, inter-individual variable genes, of which the
expression varies highly between individuals, were used to evaluate
the importance of estimating variance. When defining inter-
individual variable genes according to D quantity, variations in
gene expression were set at a level exceeding that of anatomic
variance. Therefore, when anatomic variance was considered in
the significance test, Pa is the p value of the D quantity determined
the D2 curve in Figure 2b. When anatomic variance is not
considered in the experimental design, technical variance,
evaluated by technical replication, is commonly used for the
significance test. Pt is the p value of the D quantity determined by
technical variance (D3 curve in Figure 2b).
Figure 3a plots averaged fold change versus 2 corresponding
p values (Pa and Pt) for each gene. When FDR 5% was set as
significant, 2 groups of significant genes were obtained. The
2 corresponding cutoff p values are indicated by red arrows in
Figure 3b. Averaged fold change was used as another criterion to
select inter-individual variable genes. In this study, the 4 averaged
fold changes, from 1.2 to 1.5 (the gray arrows in Figure 3b), served
as further criteria for the identification of inter-individual variable
genes.
We investigated sets of inter-individual variable genes generated
according to distinct selection criteria (different averaged fold
changes and corresponding p values) to evaluate the effects of
differing levels of variance. Figure 3c shows the number of
significant genes identified using 2 variance criteria, Pt and Pa (the
red arrows in Figure 3b), with different averaged fold changes (the
gray arrows in Figure 3b). When a higher averaged fold change
was used, the influence of variance underestimation decreased, as
shown by the number of significant genes (Figure 3c), but it paid
by reducing the number of selected genes. The difference was
eliminated when the cutoff value of averaged fold change was set
to greater than 1.3.
To evaluate the influence of variance underestimation on
biological prediction, the gene lists identified using the criteria in
Figure 3c underwent functional enrichment analysis for gene
ontology (GO) using DAVID bioinformatics resources 6.7 [50].
Among all significant genes listed in Figure 3c, only 11 common
GO terms were identified. Table 2 shows enrichment analysis
results of the 11 GO terms for the significant genes listed when
applying anatomic and technical variance with the averaged fold
change criteria 1.2 and 1.3. The enrichment results of averaged
fold change set at 1.4 and 1.5 were not listed because 2 significant
gene lists based on anatomic and technical variance were the
same. A significance score was defined as -log (p value), where the
p value represented the significance of each GO term, according
to a modified Fisher exact test in DAVID bioinformatics resources
6.7. Hence, a higher significance score represents a higher
significance for the result.
For the same GO term, the significance score for the gene set,
the p value of which was deduced by applying anatomic variance,
was usually higher than that defined by technical variance
(Table 2). This suggests that the lists of significant genes based
on technical variance might include ‘‘noisy’’ genes, which reduced
the significance of the GO terms.
Discussion
Even as simple as a single cell, its physiology are governed by
various networks, each comprising multiple signaling gene
products, which interact through positive and negative feedbacks,
as we showed previously [51]. Complexity theory, also known as
chaos theory (http://en.wikipedia.org/wiki/chaos_theory), has
Table 2. Significant score of Gene Ontology terms for the
significant gene sets determined by distinct significant
criteria.
Gene Ontology terms 1.2 fold
1 1.3 fold
1
Tech
¥ Ana
# Tech
¥ Ana
#
GO:0005576,extracellular region 8.7 9.3 4.9 4.6
GO:0005615,extracellular space 7.8 8.5 4.8 5.0
GO:0006952,defense response 7.4 8.1 5.3 5.5
GO:0044421,extracellular region part 6.4 7.2 4.2 4.4
GO:0007565,female pregnancy 2.8 3.0 2.2 2.3
GO:0009617,response to bacterium 2.4 2.6 1.6 1.6
GO:0050832,defense response to fungus 2.4 2.4 3.1 3.1
GO:0031640,killing of cells of another
organism
2.3 2.4 3.0 3.0
GO:0001906,cell killing 1.8 1.9 2.5 2.6
GO:0009620,response to fungus 1.8 1.9 2.5 2.6
GO:0042445,hormone metabolic process 1.3 1.4 2.3 2.3
The number in the table is the significant sore for GO terms. The significant
score is –log (EASE Score) where EASE Score is a modified Fisher Exact P Value
obtained by DAVID.
1The criteria of averaged fold change.
¥The significant score is evaluated by technical variance.
#The significant score is evaluated by anatomic variance.
doi:10.1371/journal.pone.0038650.t002
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complexity_home.asp) to better describe the emergent phenom-
enon of the cell. Clinical studies investigating the clinical outcomes
of individuals [52] often derive results full of noise, which can be
further grouped into intra- and inter-individual variance. There-
fore, devising analytical approaches to dissect these confounding
factors is critical.
In this study, we first collected placental tissues only from
carefully selected healthy term pregnancies, avoiding any potential
effects from maternal or fetal diseases. For a single organ, different
regions may have distinctly specialized functions, leading to
variations in gene expression [31,32]. However, this type of
variation differs between organs. The anatomic variance identified
in this study was the heterogeneous distribution of cell types within
a tissue specimen [53], prevalent in general clinical studies.
Therefore, all tissues in this study were obtained from the same
regions and same layer of the placenta to avoid biological variance
among different regions of the placenta [32]. We did not isolate
fetal trophoblasts from maternal endothelial cells in each placental
tissue because we attempted to analyze the intra- and inter-
individual variance directly from clinical tissues. To achieve this
goal, we used a loop-designed method to increase the statistical
power of microarray data analysis.
We used a test statistic, D quantity, in this study to describe
variations in gene expression between samples. The permutation
method was employed to describe the characteristics of the 3 levels
of variability. Permutation analysis is frequently adopted for
microarray studies [54–59] because distributional assumptions
(e.g., normal) using microarray data are often questionable [54]. A
non-parametric approach considering factors such as non-uniform
distributions could exhibit the characteristics of data more
appropriately. The profiles shown in Figure 2 illustrate the
differences in the 3 levels of variability, demonstrating that the
evaluation of the correct variance must be considered in the
experimental design to define statistically significant genes.
For the selection of significant genes, the results of phase I of the
MicroArray Quality Control (MAQC) project suggest that the
inter-platform reproducibility of enriched KEGG pathways and
GO terms was markedly increased when fold-change ranking in
addition to a non-stringent p value cutoff were used as the selection
criteria [60]. Thus, we used a non-stringent p value, FDR 5%, with
averaged fold change as the selection criteria. However, the
relationship between the stringency of fold change and biological
significance remains controversial. We compared the use of
4 averaged fold changes as criteria to identify the common GO
terms of all selection criteria. Pan et al. suggested that the
robustness of biological conclusions derived from microarray
analysis should be routinely assessed by examining the validity of
the conclusions using a range of threshold parameters [61]. Hence,
common GO terms are representative functions for inter-
individual variable genes. In this manner, the influence of variance
underestimation could be evaluated by using the significant scores
Figure 3. The scatter plot of averaged fold change and p values, and the selection of inter-individual variable gene. (a) The scatter
plot of log2 (averaged fold change) and –log (p value). Pa is the p value determined by applying anatomic variance. Pt is the p value determined by
applying technical variance. (b) The enlarged area of the rectangle in (a). The red arrows indicate the corresponding p value of FDR 5%. The gray
arrows indicate the averaged fold change criteria: 1.2, 1.3, 1.4, and 1.5. (c) The number of inter-individual variable gene selected by the criteria of FDR
5%, evaluated by technical and anatomic variance (The red arrows in Figure 3b), and distinct averaged fold changes (The gray arrows in Figure 3b).
doi:10.1371/journal.pone.0038650.g003
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pathways had been used to access distinct selection criteria [62].
The identification of inter-individual variable genes through
different variance levels demonstrates the importance of estimating
variance from the statistical and biological viewpoints. From the
statistical aspect, the impact of variance underestimation includes
non-statistically significant genes in the gene list (Figure 3c). From
the biological aspect, significant scores of GO terms were used to
evaluate the gene sets from distinct criteria. Table 2 shows a
summary of biological evidence for evaluating gene sets with
different significance criteria. It also shows that significant gene
sets with accurate evaluation of variance provided more accurate
biological interpretations. Our results also suggest that applying a
higher cutoff point of fold change reduced, or even eliminated, the
influence of variance underestimation. This may be a solution to
overcome the difficulties associated with the identification of
significant genes when the estimation of precise variance has not
been considered adequately in the experimental design, although it
paid by reducing the number of the final gene list.
This study demonstrated the importance of estimating variance.
Different types of biological variance should be considered,
depending on the objectives of a particular study. For example,
when using tumor and normal tissues collected from the same
individual to study the signature of a cancer [63], anatomic
variance should be considered. In clinical studies seeking to
identify biomarkers for cancer classification, in which the subject
of the experiment is of the same race, individual variance should
be considered. When experimental subjects of clinical studies
include individuals from different races, inter-population variance
should be considered. Different sampling contributes different
levels of variance, and such factors should be considered in the
experimental design and statistical model. Our results indicate that
‘‘noisy’’ genes are falsely identified as differentially expressed genes
when the level of variance is underestimated, and applying a
higher fold change as the selection criterion reduces/eliminates the
differences between distinct estimations of variance.
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